Cheryl Willman

Q: What Schools Are Affiliated With Cheryl Willman

Cheryl Willman is affiliated with the following schools: University of New Mexico, University of Washington, University of Münster

Cheryl Willman's AcademicInfluence.com Rankings

Cheryl Willman

Law

#2523

World Rank

#3138

Historical Rank

Common Law

#109

World Rank

#118

Historical Rank

law Degrees

Download Badge

Cheryl Willman's Degrees

Doctorate Medicine University of New Mexico

Why Is Cheryl Willman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Cheryl Lynn Willman is an American cancer researcher and executive director of Mayo Clinic Cancer Programs at the Mayo Clinic Comprehensive Cancer Center. Early life and education Willman was born on November 5, 1954, in Hartford City, Indiana, but she grew up in Iowa. She was born into a practicing Lutheran family as her grandfather played the church organ while her father worked as a nonordained ministry associate and administrator for the Evangelical Lutheran Church in America. Growing up, Willman attended Bettendorf High School where she served as class vice president and newspaper journalist. Upon graduating from high school, Willman enrolled at St. Olaf College where she majored in chemistry and graduated in 1977. She originally intended to enroll in law school but had become disillusioned with the American legal system due to the Vietnam War.

(See a Problem?)

Cheryl Willman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acute myeloid leukemia. (2002) (3265)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (2003) (2541)
Age and acute myeloid leukemia. (2006) (1213)
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. (2000) (1134)
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia (1999) (1053)
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. (2009) (1048)
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. (2014) (1029)
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. (1994) (945)
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. (1997) (834)
The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers (2011) (822)
All-trans-retinoic acid in acute promyelocytic leukemia. (1997) (801)
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study (2000) (731)
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. (1990) (697)
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. (2012) (661)
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. (1998) (632)
Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia (2009) (574)
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. (1999) (572)
Gene expression changes associated with progression and response in chronic myeloid leukemia. (2006) (570)
THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (2017) (569)
JAK mutations in high-risk childhood acute lymphoblastic leukemia (2009) (569)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. (2013) (536)
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia (1996) (528)
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. (2010) (512)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. (2008) (489)
Germline genomic variants associated with childhood acute lymphoblastic leukemia (2009) (473)
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. (2001) (439)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. (1996) (432)
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. (2002) (425)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. (2001) (413)
Acute Myeloid Leukemia in the Elderly : Assessment of Multidrug Resistance ( MDR 1 ) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy (1997) (397)
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. (2010) (390)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. (2010) (349)
Methylation profiling in acute myeloid leukemia. (2001) (342)
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. (2015) (289)
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2011) (286)
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis (2006) (284)
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (2017) (281)
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia (2015) (276)
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. (2012) (270)
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse (2013) (257)
Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. (2011) (256)
Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. (2016) (256)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. (2017) (253)
Drug Repurposing from an Academic Perspective. (2011) (249)
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia (2011) (244)
Pediatric acute lymphoblastic leukemia. (2003) (244)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. (2019) (239)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. (2006) (233)
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. (1995) (228)
Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). (2001) (215)
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. (2017) (214)
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. (2013) (212)
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. (2012) (207)
Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. (2012) (204)
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia (2016) (197)
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. (2006) (197)
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. (2008) (192)
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. (2002) (191)
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. (2003) (188)
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (2009) (184)
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031) (1998) (183)
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. (2012) (181)
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia (2016) (181)
HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. (1993) (180)
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. (2010) (180)
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). (1998) (178)
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. (1990) (176)
An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. (1993) (175)
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. (2006) (166)
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. (2012) (165)
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. (2013) (159)
Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual Leukemia Cells. (2016) (152)
Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study (2003) (148)
Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. (2003) (140)
Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. (2015) (131)
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. (1997) (131)
Erratum: The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (Nature Materials (2011) 10 (389-397)) (2011) (129)
Clinical and Molecular Characterization of a Rare Syndrome of Acute Promyelocytic Leukemia Associated With Translocation (2002) (123)
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. (2017) (123)
Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia [see comments] (1990) (122)
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. (2004) (121)
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. (2012) (117)
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. (2013) (116)
Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR 1 / P-Glycoprotein , MRP 1 , and LRP in Acute Myeloid Leukemia . A Southwest Oncology Group Study (1999) (115)
An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. (1998) (114)
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. (2015) (109)
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. (2016) (108)
Langerhans' cell histiocytosis (histiocytosis X): immunophenotype and growth fraction. (1993) (106)
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. (2012) (106)
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403 (2014) (105)
Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study (2010) (105)
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. (2013) (103)
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. (2008) (103)
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint (2013) (102)
Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. (1995) (99)
Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. (1995) (97)
Identification of gene expression profiles that segregate patients with childhood leukemia. (2002) (97)
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. (2015) (95)
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. (2014) (95)
Negative Regulation of Phagocytosis in Murine Macrophages by the Src Kinase Family Member, Fgr (2000) (93)
Inhibition of beta 2 integrin receptor and Syk kinase signaling in monocytes by the Src family kinase Fgr. (2001) (91)
Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. (1995) (91)
Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma (2016) (90)
Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. (2004) (89)
A Bayesian Network Classification Methodology for Gene Expression Data (2004) (89)
Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. (1990) (88)
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. (2010) (84)
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. (2018) (79)
An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. (1994) (79)
Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. (1999) (78)
Acute myelogenous leukemia and aging. Clinical interactions. (2000) (78)
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. (2011) (77)
Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1 (1989) (72)
Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia (2015) (72)
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. (2013) (71)
Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3) (2015) (70)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. (2011) (69)
Cloning and characterization of the T(15;17) translocation breakpoint region in acute promyelocytic leukemia (1990) (68)
Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. (1994) (67)
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. (2003) (67)
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. (2007) (66)
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia (2004) (66)
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906 (2011) (66)
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. (2013) (65)
Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. (2000) (64)
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. (2009) (64)
Metnase mediates chromosome decatenation in acute leukemia cells. (2009) (62)
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype (2014) (60)
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. (2013) (60)
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. (2002) (60)
Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. (2001) (60)
Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (“Ph-like” or “BCR-ABL1-Like”) Signature For Therapeutic Targeting and Clinical In (2013) (59)
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. (2000) (59)
Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia. (2000) (58)
High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL (2016) (57)
False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. (1992) (57)
Delineation of the minimal commonly deleted segment and identification of candidate tumor‐suppressor genes in del(9q) acute myeloid leukemia (2005) (57)
The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. (1997) (56)
Rearrangement of CRLF 2 is associated with mutation of JAK kinases , alteration of IKZF 1 , Hispanic / Latino ethnicity , and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia * (2010) (55)
Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. (1995) (55)
Characterization of leukemias with ETV6-ABL1 fusion (2015) (55)
Twenty‐four‐color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia (2000) (54)
Rearrangement of CRLF 2 in B-progenitor – and Down syndrome – associated acute lymphoblastic leukemia (2009) (54)
Identification of the chimeric protein product of the CBFB‐MYH11 fusion gene in inv(16) leukemia cells (1996) (54)
Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. (1991) (53)
Achievements in Understanding and Treatment of Myelodysplastic Syndromes. (2000) (50)
Abundant anti‐apoptotic BCL‐2 is a molecular target in leukaemias with t(4;11) translocation (2008) (50)
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. (2017) (50)
Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. (2007) (50)
The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. (1998) (49)
Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. (1998) (48)
Comparison of Capillary Electrophoresis and Polyacrylamide Gel Electrophoresis for the Evaluation of T and B Cell Clonality by Polymerase Chain Reaction (2000) (48)
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure (2018) (48)
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report (2013) (47)
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. (2012) (47)
PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. (2002) (47)
Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia (2014) (45)
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group (2012) (45)
Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia. (1989) (45)
Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. (2016) (45)
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. (2011) (45)
Delivery of Ricin Toxin A‐Chain by Peptide‐Targeted Mesoporous Silica Nanoparticle‐Supported Lipid Bilayers (2012) (44)
Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. (2010) (43)
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (42)
Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. (2012) (41)
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2008) (41)
Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. (1998) (39)
Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129 (2009) (38)
FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia (2001) (38)
Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). (1996) (37)
AML1-FOG2 fusion protein in myelodysplasia. (2004) (37)
Differential expression and regulation of the c-src and c-fgr protooncogenes in myelomonocytic cells. (1987) (36)
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy (2014) (36)
Trisomy 11: an association with stem/progenitor cell immunophenotype (1995) (36)
GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia (2011) (36)
Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). (1999) (36)
VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia (2014) (35)
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129. (2013) (34)
Outcome modeling with CRLF 2 , IKZF 1 , JAK , and minimal residual disease in pediatric acute lymphoblastic leukemia : a Children ’ s Oncology Group Study (2012) (33)
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia (2014) (33)
AACR Cancer Progress Report 2016 (2016) (32)
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. (2010) (32)
The genomic landscape of pediatric acute lymphoblastic leukemia (2022) (31)
Targeting JAK 1 / 2 and mTOR in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia ( ALL ) (2012) (30)
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia (2010) (29)
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500) (2007) (29)
Aggressive jejunal lymphoma of large granular lymphocytes. Immunohistochemical, ultrastructural, molecular, and DNA content analysis. (1990) (28)
Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. (2019) (28)
Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL. (2021) (28)
Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. (2014) (27)
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. (2001) (26)
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. (2000) (25)
Trisomy 6 as a primary karyotypic aberration in hematologic disorders. (1998) (25)
Multiparameter analysis of acute mixed lineage leukemia: correlation of a B/myeloid immunophenotype and immunoglobulin and T-cell receptor gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology. (1991) (24)
Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project. (2009) (24)
Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. (2003) (23)
Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. (1994) (23)
Integrin α6 mediates drug resistance of acute lymphoblastic B-cell leukemia. (2020) (22)
Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. (1996) (22)
Relapse of acute promyelocytic leukemia with PML-RARα mutant subclones independent of proximate all-trans retinoic acid selection pressure (2006) (22)
Oncogenes, suppressor genes, and carcinogenesis. (1987) (22)
Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic. (2011) (21)
Aberrant STAT 5 and PI 3 K / mTOR pathway signaling occurs in human CRLF 2-rearranged B-precursor acute lymphoblastic leukemia (2012) (21)
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia (2018) (20)
Molecular genetic approaches for the diagnosis of clonality in lymphoid neoplasms. (1990) (20)
The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. (1996) (20)
Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities (2020) (19)
A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization. (2004) (19)
Nonleukemic granulocytic sarcoma of the heart: A report of a fatal case (1987) (19)
Discovery of novel molecular classification schemes and genes predictive of outcome in leukemia. (2004) (19)
Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (17)
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia (2006) (17)
The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia (2013) (17)
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020) (16)
Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials (2006) (16)
N-ras Mutations in Acute Myelogenous Leukemia: A Review of the Current Literature and an update of the Southwest Oncology Group Experience (1992) (15)
Molecular evaluation of acute myeloid leukemias. (1999) (15)
Characterization and Use of an Antibody Detecting the CBFβ-SMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias (1998) (14)
Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432). (2007) (14)
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia (2022) (14)
Cloning of the murine c-fgr proto-oncogene cDNA and induction of c-fgr expression by proliferation and activation factors in normal bone marrow-derived monocytic cells. (1989) (14)
General principles of multiparameter flow cytometric analysis: applications of flow cytometry in the diagnostic pathology laboratory. (1989) (13)
The molecular biology of acute myeloid leukemia. Proto-oncogene expression and function in normal and neoplastic myeloid cells. (1990) (13)
Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710 (2011) (13)
SH2B3: a new leukemia predisposition gene. (2013) (13)
Frequency and Clinical Signiﬁcance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study (1999) (12)
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance) (2018) (12)
Three-color versus four-color multiparameter cell cycle analyses of primary acute myeloid leukemia samples. (2000) (12)
A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232 (2011) (12)
Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. (2010) (11)
Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. (1999) (11)
Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. (2006) (11)
report from The Children's Oncology Group TARGET Project Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a (2012) (11)
Commentary: Is Langerhans cell histiocytosis a myeloid dendritic stem cell disorder related to myelodysplastic disorders? (2000) (11)
Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome (2013) (11)
Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML? (2008) (9)
High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults (2015) (9)
Orien (2016) (9)
Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial. (2009) (8)
Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. (2009) (8)
Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study. (2006) (8)
Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia (2013) (8)
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial (2020) (8)
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. (2017) (8)
Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia (2011) (8)
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605) (2010) (8)
Prognostic markers in acute leukemia (1996) (7)
Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99. (2004) (7)
FLT 3 Mutation Status is a Predictor of Early Death in Pediatric Acute Promyelocytic Leukemia : A Report From The Children ' s Oncology Group (7)
Pediatric acute lymphoblastic leukemia . Pediatric Acute Lymphoblastic Leukemia (2018) (6)
Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232 (2011) (6)
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (6)
The Biology of Acute Lymphoblastic Leukemia (2011) (6)
Molecular Diagnostics in Pathology (1991) (6)
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905 (2019) (6)
Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project (2013) (6)
Cell-Speci fi cDelivery of Diverse Cargos byBacteriophageMS 2 Virus-likeParticles (2011) (6)
Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction (2004) (6)
Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group (2016) (6)
Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129 (2011) (6)
Endoscopic "salvage" cytology in neoplasms metastatic to the upper gastrointestional tract. (1986) (5)
Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (2015) (5)
A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients (2012) (5)
Is Langerhans cell histiocytosis a myeloid dendritic stem cell disorder related to myelodysplastic disorders? (2000) (5)
The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia (2019) (5)
Molecular biology and the pathologist. General principles and applications. (1987) (5)
A Gene Expression Classifier for Improved Risk Classification and Outcome Prediction in Pediatric Acute Lymphoblastic Leukemia (ALL). (2005) (5)
The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia (2015) (5)
Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias. (1998) (5)
Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling (2010) (5)
Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance (2020) (5)
Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Study C9710. (2010) (5)
Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL) (2011) (5)
The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003 (2016) (4)
Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project (2010) (4)
Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group (2020) (4)
Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710 (2007) (4)
Correction: Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia (2016) (4)
Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG) (2015) (4)
Regularization Strategies for Hyperplane Classifiers: Application to Cancer Classification with gene Expression Data (2006) (4)
High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy (2016) (4)
iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies (2011) (4)
Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report (2020) (3)
Orien: Reshaping Cancer Research & Treatment (2016) (3)
Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL -Rearranged Leukemias (2008) (3)
Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report (2013) (3)
Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia (2014) (3)
The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group (COG) Studies AALL0331 and AALL0232. (2014) (3)
Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children's Oncology Group (COG) study P9900 (2008) (3)
Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (2015) (3)
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial (2022) (3)
Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. (2005) (2)
Abstract 4729: Frequency of actionable gene fusions in patients with Philadelphia chromosome-like (Ph-like) B-acute lymphoblastic leukemia (ALL): A retrospective study from the Children's Oncology Group (COG) (2015) (2)
AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group (1998) (2)
Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia (2010) (2)
The Presence of bcl‐1 and bcl‐2 Gene Rearrangements in Diffuse Small Cleaved‐Cell Lymphoma: A Disease with Diverse Molecular and Immunophenotypic Findings (1994) (2)
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia (2020) (2)
PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia (2012) (2)
PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL) (2013) (2)
Use of Genomic Technologies to Identify Novel Genetic Abnormalities and Therapeutic Targets In Acute Lymphoblastic Leukemia. (2008) (2)
Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group. (2011) (2)
Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations. (2005) (2)
The case for American Board of Pathology certification in molecular pathology. (1995) (2)
Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG) (2020) (2)
Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG (2011) (2)
Assessing Knowledge and Perceptions About Cancer Among American Indians of the Zuni Pueblo, NM (2021) (2)
Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710. (2006) (2)
Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL. (2006) (1)
novel biologic clusters for risk classification and outcome prediction Gene expression profiling of adult acute myeloid leukemia identifies (2008) (1)
High throughput instruments, methods, and informatics for systems biology. (2003) (1)
Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance) (2014) (1)
Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia (2015) (1)
Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism (2016) (1)
All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia (2001) (1)
Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group (2016) (1)
A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol--Report on the good-risk patients. (2012) (1)
Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients. (2010) (1)
Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling. (2008) (1)
Targeted Delivery of Protein Toxins: Delivery of Ricin Toxin A‐Chain by Peptide‐Targeted Mesoporous Silica Nanoparticle‐Supported Lipid Bilayers (Adv. Healthcare Mater. 3/2012) (2012) (1)
ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (2010) (1)
FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421. (2004) (1)
Children with t(12;21)/TEL-AML1-Positive Acute Lymphoblastic Leukemia Exhibit a Distinct Germline Genomic Signature. (2007) (1)
Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG, (2011) (1)
Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. (2006) (1)
In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL). (2012) (1)
pediatric B-precursor acute lymphoblastic leukemia residual disease improve risk classification and outcome prediction in Gene expression classifiers for relapse-free survival and minimal (2010) (1)
diagnosis to relapse in childhood acute lymphoblastic leukemia Genome-wide copy number profiling reveals molecular evolution from (2013) (1)
Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project (2013) (1)
Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants. (2008) (1)
Abstract PR02: Investigating the use of tyrosine kinase inhibitors in Ph-like ALL. (2015) (1)
Gene expression proﬁles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study (2012) (1)
Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud. (2012) (1)
Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations (2012) (1)
Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets from ECOG and SWOG Trials (2012) (1)
Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial (2010) (1)
Isolation and characterization of the murine C-FGR genomic locus: exons IB-XII. (1995) (1)
Quantitative analysis ofMDRI(multidrug resistance) gene expression inhumantumors bypolymerase chain reaction (1990) (1)
Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study (2010) (1)
Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia (2008) (1)
Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia (2014) (1)
Abstract 4369: Rearrangements of the erythropoietin receptor are recurrent in Ph-like acute lymphoblastic leukemia and are sensitive to Jak2 inhibition (2015) (1)
Abstract PL03-05: A framework for community-engaged participatory research in cancer genomic sequencing: A collaborative with sovereign tribal nations in the American southwest (2022) (1)
Resolution of ambiguous low‐level positive quantitative polymerase chain reaction results in TEL‐AML1 positive ALL using a post‐PCR fluorescent oligoligation method * (2006) (1)
Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL). (2005) (1)
Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL (2013) (1)
Appendix : supplementary information : gene expression profiling reveals novel genes for improved risk classification and outcome prediction in pediatric acute lymphoblastic leukemia : identification, validation, and cloning of OPAL1. (2004) (1)
Up-Regulation of Genes Involved in Folate Metabolism Characterize Late but Not Early Relapse in Childhood Acute Lymphoblastic Leukemia. (2009) (1)
Relationships between polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from Southwest Oncology Group 9031 and 9333 clinical trials (2005) (0)
Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. (2012) (0)
Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report (2021) (0)
Cell-specific delivery by bacteriophage Single-molecule trapping Biofunctional quantum dots (2011) (0)
DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report, (2011) (0)
Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL (2012) (0)
A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance) (2014) (0)
Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia (2014) (0)
Genome-wide association study identiﬁes germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia (2012) (0)
Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report (2019) (0)
Molecular Assessment of Clonality in Hematopoietic Lesions: Disease Applications (1995) (0)
Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes. (2011) (0)
Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study. (2012) (0)
203 Molecular biology of elderly AML and its relationship to myelodysplasia (MDS) (1997) (0)
Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia (2008) (0)
Oncology Group/Eastern Cooperative Oncology Group study postremission therapy in adult acute myeloid leukemia: a Southwest Karyotypic analysis predicts outcome of preremission and (2013) (0)
Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421. (2004) (0)
Evaluation of the In Vitro and In Vivo Ef ﬁ cacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia (2015) (0)
BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia (2011) (0)
Abstract B044: Assessing knowledge and perceptions about cancer among American Indians of Zuni Pueblo, New Mexico (2020) (0)
Integrated analysis of 179 validated somatic sequence mutations with genome-wide copy number alterations and gene expression profiles revealed a high frequency of recurrent somatic alterations in key signaling pathways including B cell development/differentiation (2011) (0)
Application of Multidisciplinary Analysis to Gene Expression (2004) (0)
OP17 Arsenic trioxid improves survival in first line APL consolidation treatment: the NCI/CALGB study results (2007) (0)
Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients (2010) (0)
Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report (2016) (0)
Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia (2014) (0)
Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL (2012) (0)
leukemia postconsolidation therapy in younger patients with acute myeloid A phase 3 study of gemtuzumab ozogamicin during induction and (2013) (0)
acute lymphoblastic leukemia Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like (2012) (0)
SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). (2013) (0)
Oncology Group Study disease in pediatric acute lymphoblastic leukemia: a Children's , and minimal residual (2012) (0)
Characterization of new cryptic rearrangements of the erythropoietin receptor in Ph-like acute lymphoblastic leukemia (2015) (0)
Identification of a Novel Alternatively Spliced Form of AML1-ETO and Analysis of Its Role in Leukemogenesis. (2004) (0)
Recurrent MEF2D Fusions Define A New Subtype of Acute Lymphoblastic Leukemia Associated with Older Age at Diagnosis and Poor Outcome (2016) (0)
Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival. (2005) (0)
Select gamma-Secretase Inhibitors Induce Apoptosis in Pre-B ALL Cells and Disrupt the Balance Between Constitutive Notch Signaling and Repression. (2008) (0)
RAPID Characterization and Use of an Antibody Detecting the CBF (cid:98) -SMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias (1998) (0)
Abstract PR-2: Characterization of germline genetic variants underlying racial disparities of childhood leukemia outcome (2009) (0)
Abstract SY14-04: Cancer health disparities in American Indian and Alaskan Native populations (2017) (0)
Glutathione S-Transferase Theta 1 Gene Deletion and Risk of Acute Myeloid Leukemia 1 (2000) (0)
pediatric B-progenitor acute lymphoblastic leukemia , Hispanic / Latino ethnicity , and a poor outcome in IKZF 1 alteration of kinases , JAK is associated with mutation of CRLF 2 Rearrangement of (2010) (0)
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020) (0)
lymphoblastic leukemia: a report from the Children's Oncology Group Key pathways are frequently mutated in high-risk childhood acute (2013) (0)
Abstract B04: Investigating the use of tyrosine kinase inhibitors in Ph-like ALL. (2015) (0)
adult patients with acute lymphoblastic leukemia Connective tissue growth factor (CTGF) expression and outcome in (2013) (0)
Expression Profiling Identifies Novel Genetic Subgroups with Distinct Clinical Features and Outcome in High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia (B-ALL). A Children’s Oncology Group Study. (2007) (0)
Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study. (2007) (0)
Modeling Resistance To Tyrosine Kinase Inhibitors In TEL/ABL-Positive Acute Lymphoblastic Leukemia (2013) (0)
Brief report Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia (2007) (0)
PRESIDENT ’ S CANCER PANEL AMERICA ’ S DEMOGRAPHIC AND CULTURAL TRANSFORMATION : IMPLICATIONS FOR THE CANCER ENTERPRISE (2009) (0)
Hematopoietic Cell Expression of OPAL1, an Outcome Predictor in Pediatric Acute Lymphoblastic Leukemia. (2005) (0)
Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia (2016) (0)
CTGF (CCN2) Predicts OS and DFS in Adult Acute Lymphoblastic Leukemia. (2005) (0)
Pediatric Acute Lymphoblastic Leukemia Outcome Predictor Genes OPAL1 and RANTES Modulate Transformation by the V-Abl Oncogene (2008) (0)
KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. (2023) (0)
Treatment-inﬂuenced associations of PML-RAR (cid:1) mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia (2012) (0)
Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children’s Oncology Group Trials. (2008) (0)
Relapsed childhood ALL: Gaining insights and identifying targets by gene expression profiling (2005) (0)
Abstract 998: Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukemia (B-ALL): A report from the children's oncology group (COG) - Target - St. Jude Pediatric Cancer Genome Project (2014) (0)
Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children’s Oncology Group (COG) Study. (2008) (0)
A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. (2012) (0)
Gene Signatures Predictive of Outcome in Higher Risk Childhood Acute Lymphoblastic Leukemia (ALL). (2005) (0)
Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG (2021) (0)
Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group. (2007) (0)
Resistance in Patients ' Tumors : Consensus Recommendations Methods to Detect P-Glycoprotein-associated Multidrug Updated (2006) (0)
Genome-wide copy number proﬁling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia (2008) (0)
Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia (2014) (0)
Inherited GATA3 genetic Variants Are Associated With Childhood BCR-ABL1-Like Acute Lymphoblastic Leukemia and Increased Risk Of Relapse (2013) (0)
Outcome Predictor in Acute Leukemia 1 (OPAL1) Predicts Outcome in Pediatric Acute Lymphoblastic Leukemia in Multiple Independent Gene Expression Data Sets: Effects of Binary Binning, a Statistical Approach (2007) (0)
Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia. (2009) (0)
Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles ( 90 Days): A Children's Oncology Group Study (2010) (0)
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network. (2023) (0)
Drug repurposing Drug repurposing from an academic perspective (2012) (0)
Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia. (2012) (0)
ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL (2012) (0)
Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. (2010) (0)
Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia (2013) (0)
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients (2023) (0)
KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report (2011) (0)
patients from intergroup protocol 0129 promyelocytic leukemia: assessment of prognostic significance in adult mRNA in acute α Quantitative real-time RT-PCR analysis of PML-RAR (2013) (0)
Group study compared to cytarabine and daunorubicin: a Southwest Oncology myeloid leukemia is not improved with mitoxantrone and etoposide Outcome after induction chemotherapy for older patients with acute (2013) (0)
Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report (2021) (0)
Defining blast characteristics in relapsed childhood acute lymphoblastic leukemia using gene expression profiling. (2004) (0)
LYMPHOID NEOPLASIA SOX 4 enables oncogenic survival signals in acute lymphoblastic leukemia (2012) (0)
Expression of Midkine(MDK) and Sensitivity to Anti-Leukemic Drugs in Pediatric Acute Lymphoblastic Leukemia (ALL). (2007) (0)
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. (2004) (0)
Increments in Acute Myeloid Leukemia Cells Cholesterol Synthesis and Import Contribute to Protective Cholesterol (2013) (0)
Evaluationof the InVitro and InVivo Ef fi cacyof the JAK Inhibitor AZD 1480 against JAK-Mutated Acute Lymphoblastic Leukemia (2015) (0)
Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia (2014) (0)
Supplementary Table 3A (2011) (0)
FLT3,RAS, andTP53mutations in elderly patients with acute myeloid leukemia (2001) (0)
Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study. (2007) (0)
A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia (2013) (0)
polymerase chain reaction in acute myelogenous leukemia containing An AML1/ETO fusion transcript is consistently detected by RNA-based (2011) (0)
Identification of Gfi1 as a Direct Target of the Leukemogenic Fusion Protein AML1-ETO9a (2008) (0)
BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance (2012) (0)
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia (2020) (0)

This paper list is powered by the following services:

Other Resources About Cheryl Willman

en.wikipedia.org

What Schools Are Affiliated With Cheryl Willman?

Cheryl Willman is affiliated with the following schools:

Cheryl Willman's Academic­Influence.com Rankings